Search results
8 paź 2024 · Merck’s (NYSE: MRK) Q1 2024 results reflect continued strong growth in oncology and vaccines. Our company announced Q1 worldwide sales of $15.8 billion, an increase of 9% from Q1 2023. “Merck has begun 2024 with continuing momentum in our business.
- Email Alerts
Contact investor relations (732) 594-1468....
- Events & Presentations
Explore Merck's investor events and presentations. Merck is...
- Stock Information
Merck is the world's premier research-intensive,...
- Financial Information
investor_relations@merck.com. Explore our quarterly reports,...
- Investor Resources
investor_relations@merck.com. Related links. Stock...
- SEC Filings
Review Merck & Co.’s financial catalog of past SEC filings...
- Organon Resources
Contact investor relations (732) 594-1468....
- Email Alerts
Welcome to Investor Relations at Merck. Here you’ll find everything you might be interested in if you like to be invested in vibrant science and technology, and become or stay part of the Merck investor community.
Explore Merck's investor events and presentations. Merck is the world's premier research-intensive, purpose-driven biopharmaceutical company.
Merck keeps growing profitably. The excellent performance of our business shows that we are on the right track. See for yourself in our detailed reports and financials.
Learn about Merck's strategy, financial performance and future plans at various events and webcasts. Find out the dates and details of Capital Market Days, Annual General Meeting and other investor relations events.
3 lut 2022 · KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the fourth quarter and full year of 2021.
Find quarterly and annual reports, webcasts, SEC filings and other financial disclosures of Merck, the world's premier research-intensive biopharmaceutical company. Sign up for email alerts and contact investor relations for questions.
